---
created: 2025-04-13
updated: 2025-04-13T10:53
id: o>TZDe&~4_
specialty: pharmaco
specialty_id: 332
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::20-sorafenib-sunitinib
  - "source/ak-step1-v11:": 
  - source/ome-banner
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::08-antineoplastics::03-kinase-inhibitors-&-monoclonal-antibodies::01-imatinib,-erlotinib,-sorafenib,-sunitinib,-vemurafenib::zanki-extra
  - source/ak-step1-v11::^other::^expn
  - source/ak-step1-v11::^other::^highyield::2-relativelyhighyield"
type: flashcard
---

# Question
Because sorafenib targets VEGF, areas that are highly vascularized will be affected such as the **skin** and the **kidney**

---

# Answer
